Given that anti-Grem1 antibody treatment demonstrated the greatest antitumor effect during early stages of disease, where tumor burden was still limited, this therapy would be well suited in the maintenance phase of treatment where MM PC tumors may still be widespread, but of small size. This evidence concerns the gene GREM1 and pachyonychia congenita.